trastuzumab deruxtecan
EMA to Review Daiichi Sankyo, AstraZeneca's Enhertu For Second-Line HER2-Positive Breast Cancer
The EMA validated a Type II Variation Application for Enhertu in advanced, HER2-positive breast cancer patients after at least one HER2-targeted therapy.
Daiichi Sankyo, AstraZeneca Begin Phase III Trial of Enhertu in HER2-Mutant NSCLC
The study is comparing Enhertu to standard-of-care chemotherapy plus immunotherapy as a first-line treatment for advanced NSCLC patients with HER2 mutations.
SABCS Clinicogenomic Study Sheds Light on HER2-Targeted Therapy Resistance
Genomic sequencing on 733 HER2-positive advanced breast cancer patients revealed mechanisms of anti-HER2 treatment resistance and potential therapeutic solutions.
AstraZeneca, Daiichi Sankyo Unveil First Datopotamab Deruxtecan TNBC Data at SABCS
The companies will conduct a Phase III trial of datopotamab deruxtecan following positive results from a Phase I TNBC cohort presented at the meeting.
AstraZeneca's Q3 Oncology Revenues Grow 18 Percent
The company's oncology segment contributed 34 percent of total revenues and brought in $3.38 billion during the quarter.
Jul 29, 2021
AstraZeneca Q2 Revenues Increase 31 Percent
Mar 22, 2021